Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
March 25, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign
March 19, 2024 09:15 ET
|
American Kidney Fund
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as...
American Kidney Fund Convenes Nation’s Kidney Community for 2024 Kidney Action Week™ March 18-22
March 18, 2024 09:47 ET
|
American Kidney Fund
ROCKVILLE, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) kicks off its fifth annual Kidney Action Week™, the nation’s only free online conference that draws patients,...
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease
March 15, 2024 08:59 ET
|
American Kidney Fund
ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate...
Unicycive Announces $50 Million Private Placement
March 14, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 13, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 ...
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 07, 2024 16:12 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
March 04, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
February 29, 2024 14:44 ET
|
American Kidney Fund
ROCKVILLE, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The first day of March marks the beginning of Kidney Month, a month in which the American Kidney Fund (AKF) will mark 31 days of action that will...
Where You Live Impacts Your Ability to Save a Life Through Living Organ Donation, According to the 2024 American Kidney Fund Report Card
February 22, 2024 09:24 ET
|
American Kidney Fund
ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today released its fourth annual State of the States: Living Donor Protection Report Card with updates highlighting...